comparing the efficacy and safety ofintralesional acyclovir in two concentration in common warts
Phase 4
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2024/02/063057
- Lead Sponsor
- Dr RPGMC Kangra at Tanda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Warts <10 in number
Exclusion Criteria
Pregnant and lactating women
Children <12 years
Hypersensitivity to acyclovir
Patients with multiple warts ( >10)
Patients who received any other treatment for warts at least 1 month before the study
Patients on antiviral medication for other indications
Not willing to participate or give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method resolution of wartsTimepoint: period interval of 2 weeks, 4 weeks, 6 weeks and 8 weeks.
- Secondary Outcome Measures
Name Time Method comparing efficacy & safety of intralesional acyclovir in concentration of 70mg per ml vs 100mg per mlTimepoint: period interval of 2 weeks 4weeks 6 weeks 8 weeks